Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06DZI
|
|||
| Former ID |
DNC003505
|
|||
| Drug Name |
GR-127935
|
|||
| Synonyms |
148672-13-3; GR 127935; GR-127935; N-(4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-carboxamide; GR127935; UNII-2LLH6CEB40; 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide; 2LLH6CEB40; CHEMBL15928; GR 127935 hydrochloride hydrate; N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE; CHEBI:64114; GR 127935 HCl; C29H31N5O3
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Terminated | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H31N5O3
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C
|
|||
| InChI |
1S/C29H31N5O3/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34/h5-12,17-18H,13-16H2,1-4H3,(H,31,35)
|
|||
| InChIKey |
YDBCEBYHYKAFRX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 148672-13-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7361807, 7979276, 10234434, 11111230, 11114099, 14908719, 44436737, 47500600, 47574454, 47647601, 49894171, 50104861, 53788924, 57338245, 79039682, 85209088, 85787609, 90340955, 91704291, 103046600, 103178924, 103984442, 104379719, 124750000, 124880216, 124880217, 124880218, 125748894, 129778270, 134340710, 135066838, 135610571, 135650312, 135697554, 144240003, 152254722, 160830080, 162221927, 163094387, 163394389, 163843137, 172907935, 179235759, 184527350, 184538716, 198985096, 204365925, 223532823, 224977084, 233367607
|
|||
| ChEBI ID |
CHEBI:64114
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1B receptor (HTR1B) | Target Info | Modulator | [3] |
| 5-HT 1D receptor (HTR1D) | Target Info | Modulator | [3] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 14). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002743) | |||
| REF 3 | GR127935: a potent and selective 5-HT1D receptor antagonist.Behav Brain Res.1996;73(1-2):157-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.